Day One Biopharmaceuticals Inc’s filing revealed that its GENERAL COUNSEL Dubow Adam unloaded Company’s shares for reported $44825.0 on Aug 16 ’24. In the deal valued at $14.00 per share,3,202 shares were sold. As a result of this transaction, Dubow Adam now holds 26,928 shares worth roughly $0.38 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, York Charles N II sold 2,633 shares, generating $36,860 in total proceeds. Upon selling the shares at $14.00, the COO, CFO AND SECRETARY now owns 232,485 shares.
Before that, Blackman Samuel C. sold 2,232 shares. Day One Biopharmaceuticals Inc shares valued at $31,246 were divested by the HEAD OF R&D at a price of $14.00 per share. As a result of the transaction, Blackman Samuel C. now holds 1,127,535 shares, worth roughly $15.89 million.
BofA Securities upgraded its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy from a an Underperform in a research note published on August 01, 2024; the price target was increased to $24 from $11. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in late April has reiterated a ‘”a Buy”‘ rating for it. BofA Securities also remained covering DAWN and has decreased its forecast on April 25, 2023 with a “an Underperform” recommendation from previously “Buy” rating. CapitalOne started covering the stock on February 08, 2023. It rated DAWN as “an Overweight”.
Price Performance Review of DAWN
On Friday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 3.00% to $14.09. Over the last five days, the stock has gained 1.22%. Day One Biopharmaceuticals Inc shares have fallen nearly -3.49% since the year began. Nevertheless, the stocks have risen 4.29% over the past one year. While a 52-week high of $18.07 was reached on 05/01/24, a 52-week low of $9.67 was recorded on 06/17/24. SMA at 50 days reached $14.14, while 200 days put it at $14.35.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 13.84, which if violated will result in even more drops to 13.58. On the upside, there is a resistance level at 14.26. A further resistance level may holdings at 14.43. The Relative Strength Index (RSI) on the 14-day chart is 50.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 23.28%. Stochastics%K at 72.57% indicates the stock is a holding.
How much short interest is there in Day One Biopharmaceuticals Inc?
A steep rise in short interest was recorded in Day One Biopharmaceuticals Inc stocks on 2024-07-31, growing by 1.77 million shares to a total of 12.21 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 10.44 million shares. There was a rise of 14.46%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 03, 2023 when Oppenheimer began covering the stock and recommended ‘”a Perform”‘ rating.
